Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immunobladder
- Development stage
- Unknown
- Lead developer
- Japan BCG Laboratory
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravesical
01
Overview
Immunobladder is a live BCG-based immunotherapy developed and manufactured by Japan BCG Laboratory for the treatment of non-muscle-invasive bladder cancer (NMIBC). The product contains the freeze-dried BCG Tokyo 172 strain, which is administered directly into the bladder via intravesical instillation. Its mechanism of action involves the attachment and internalization of the BCG bacteria by bladder cancer cells, which triggers a robust localized inflammatory and immune response. This activation leads to the production of various cytokines and the recruitment of immune effector cells, such as T-lymphocytes, natural killer (NK) cells, and macrophages, which collectively target and destroy the malignant cells. Immunobladder is approved in Japan and several other countries as a standard-of-care treatment for preventing recurrence in high-risk NMIBC and for treating carcinoma in situ (CIS) of the urinary bladder.
- Brand names
- ImmunobladderImmunobladder Intravesical
- Other names
- BCG Tokyo 172 strainFreeze-Dried BCG Tokyo 172 strain
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Immunobladder.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunobladder.